Heterogeneous nucleation of the primary phase in the rapid solidification of Al-4.5wt%Cu alloy droplet

International audienceThis paper reports on rapid solidification of Al-Cu alloys. A heterogeneous nucleation/growth model coupled with a thermal model of a falling droplet through a stagnant gas was developed. The primary undercooling as well as the number of nucleation points was compared with Al-Cu alloy droplets produced by Impulse Atomization (IA). Based on experimental results from Neutron Diffraction, secondary (eutectic) phases were obtained. Then, primary and secondary undercoolings were estimated using the metastable extensions of solidus and liquidus lines calculated by Thermo-Calc. Moreover, Synchrotron X-ray micro-tomography has been performed on Al-4.5wt%Cu droplets. The undercoolings are in good agreement. Results also evidence the presence of one nucleation point and are in agreement with the experimental observations. 1. Introduction Manufacturing of most metallic alloy products involves solidification at some stage. Mechanical properties of these products are generally related to their solidification microstructures. Depending on the final application of a product, a certain type of microstructure is more appropriate compared to another. For a product that requires directional properties, a microstructure of columnar grains is needed while isotropic properties are satisfied with an equiaxed structure. Generally, post-processing of the solidified materials is required to obtain the final product with desired properties. These post-solidification treatments are generally time-consuming and therefore increase the production cost without fully eliminating solidification related defects such as segregation. Therefore, it is important to understand all the dynamics involved in the formation of solidification microstructures in order to control the properties of the final products. As dendrites growth from an undercooled melt depends a great deal on the nucleation undercooling. Therefore, determination of undercooling and the resulting growth rate, recalescence, microsegregation/phase fraction and grain size is very important. Al-Cu alloys (4.5, 5, 10 and 17 wt% Cu) have been produced by IA and the last three compositions were analysed in our previous papers [1, 2]. IA is a single fluid atomization technique that is capable of producing droplets of controlled size having a relatively narrow distribution and a predictable cooling rate. The alloys (350 to 450g) were melted in a graphite crucible by means of an induction furnace and atomized at 850ºC in an almost oxygen free chamber (10ppm) under Nitrogen, Helium or Argon atmospheres. The atomized droplets rapidly solidify during their fall by losing heat to th

Theory of Banana Liquid Crystal Phases and Phase Transitions

We study phases and phase transitions that can take place in the newly discovered banana (bow-shaped or bent-core) liquid crystal molecules. We show that to completely characterize phases exhibited by such bent-core molecules a third-rank tensor $T^{ijk}$ order parameter is necessary in addition to the vector and the nematic (second-rank) tensor order parameters. We present an exhaustive list of possible liquid phases, characterizing them by their space-symmetry group and order parameters, and catalog the universality classes of the corresponding phase transitions that we expect to take place in such bent-core molecular liquid crystals. In addition to the conventional liquid-crystal phases such as the nematic phase, we predict the existence of novel liquid phases, including the spontaneously chiral nematic $(N_T + 2)^*$ and chiral polar $(V_T + 2)^*$ phases, the orientationally-ordered but optically isotropic tetrahedratic $T$ phase, and a novel nematic $N_T$ phase with $D_{2d}$ symmetry that is neither uniaxial nor biaxial. Interestingly, the Isotropic-Tetrahedratic transition is {\em continuous} in mean-field theory, but is likely driven first-order by thermal fluctuations. We conclude with a discussion of smectic analogs of these phases and their experimental signatures.Comment: 28 pgs. RevTex, 32 eps figures, submitted to Phys. Rev.

Enhanced fluctuations of the tunneling density of states near bottoms of Landau bands measured by a local spectrometer

We have found that the local density of states fluctuations (LDOSF) in a disordered metal, detected using an impurity in the barrier as a spectrometer, undergo enhanced (with respect to SdH and dHvA effects) oscillations in strong magnetic fields, omega _c\tau > 1. We attribute this to the dominant role of the states near bottoms of Landau bands which give the major contribution to the LDOSF and are most strongly affected by disorder. We also demonstrate that in intermediate fields the LDOSF increase with B in accordance with the results obtained in the diffusion approximation.Comment: 4 pages, 4 figure

Enhanced Fluctuations of the Tunneling Density of States near the Bottom of a Landau Band Measured by a Local Spectrometer

We have found that the local density of state fluctuations (LDOSF) in a disordered metal, detected using an impurity in the barrier as a spectrometer, undergo enhanced (with respect to Shubnikov -de Haas and de Haas -van Alphen effects) oscillations in strong magnetic fields, v c t 1. We attribute this to the dominant role of the states near the bottom of Landau bands which give the major contribution to the LDOSF and are most strongly affected by disorder. We also demonstrate that in intermediate fields the LDOSF increase with field B in accordance with the results obtained in the diffusion approximation. PACS numbers: 73.23.Hk, 72.15.Gd, 73.20.Fz, 73.40.Ty Resonant tunneling through individual impurities has been identified and studied in vertical In this paper, we study the evolution with magnetic field of the LDOSF in a 3D disordered metal, a heavily doped semiconductor, and discuss the results from the point of view of the fluctuation and correlation properties of single-particle wave functions in disordered media. We have measured the fingerprint of the LDOSF, dn͑´͒, in the differential conductance G͑V ͒ dI dV ͑V ͒ in a broad range of magnetic fields, B, and analyzed its variance, ͗dG 2 ͘, and correlation parameters. In intermediate fields, v c t ϳ 1, we have detected an increase of the fluctuation magnitude, in agreement with the theoretically predicted behavior [11]: ͗͑dG͒ 2 ͘ B ͗͑͞dG͒ 2 ͘ B0 ഠ 1 1 ͑v c t͒ 2 . At higher fields, v c t 1, we have observed large 1͞B periodic oscillations in ͗dG 2 ͘. We conclude that LDOSF in strong fields are dominated by the states near the minimum of the Landau bands which play a distinguished role relative to the rest of the spectrum. Notably, the observed oscillations are significantly stronger than those in other oscillatory effects in metals, such as de Haas-van Alphen effect. The investigated structure consists of a 50 Å GaAs well imbedded between two 81 Å Al 0.33 Ga 0.67 As barriers. Each Si-doped GaAs contact consists of three layers: 4800 Å with nominal doping 10 18 cm 23 is followed by 4800 Å with 2 3 10 17 cm 23 , and the latter is separated from the barrier by an undoped spacer of 300 Å and 200 Å, for top and bottom contact, respectively. The lateral area of the nominally undoped quantum well is reduced to a 700 Å diameter disk using the ion bombardment technique At zero bias, the spectrometer level S is above the Fermi level m of the emitter with 3D metallic conduction. The alignment of S and m with increasing bias is registered as a step in IV . In the differential conductance G͑V ͒ shown in and its width is related to the energetic width of the spectrometer G Ӎ G max Ӎ 120 meV determined by the tunneling coupling between the impurity and the contacts. The values of G min,max depend on the transparencies of the two barriers, so that G max corresponds to the lower (collector) barrier and G min corresponds to the higher (emitter) barrier, G min ϳ 5 3 10 23 G max , as estimated from the value of G G . The relation between bias V and the energy scale of the spectrometer is established by the coefficientf b dE d͑eV ͒ 0.24, found for the selected 0031-9007͞00͞84(7)͞1563(4)$15.0

Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease)

BACKGROUND: The World Health Organization (WHO) advises treatment of Mycobacterium ulcerans disease, also called "Buruli ulcer" (BU), with a combination of the antibiotics rifampicin and streptomycin (R+S), whether followed by surgery or not. In endemic areas, a clinical case definition is recommended. We evaluated the effectiveness of this strategy in a series of patients with large ulcers of > or =10 cm in longest diameter in a rural health zone of the Democratic Republic of Congo (DRC). METHODS: A cohort of 92 patients with large ulcerated lesions suspected to be BU was enrolled between October 2006 and September 2007 and treated according to WHO recommendations. The following microbiologic data were obtained: Ziehl-Neelsen (ZN) stained smear, culture and PCR. Histopathology was performed on a sub-sample. Directly observed treatment with R+S was administered daily for 12 weeks and surgery was performed after 4 weeks. Patients were followed up for two years after treatment. FINDINGS: Out of 92 treated patients, 61 tested positive for M. ulcerans by PCR. PCR negative patients had better clinical improvement than PCR positive patients after 4 weeks of antibiotics (54.8% versus 14.8%). For PCR positive patients, the outcome after 4 weeks of antibiotic treatment was related to the ZN positivity at the start. Deterioration of the ulcers was observed in 87.8% (36/41) of the ZN positive and in 12.2% (5/41) of the ZN negative patients. Deterioration due to paradoxical reaction seemed unlikely. After surgery and an additional 8 weeks of antibiotics, 98.4% of PCR positive patients and 83.3% of PCR negative patients were considered cured. The overall recurrence rate was very low (1.1%). INTERPRETATION: Positive predictive value of the WHO clinical case definition was low. Low relapse rate confirms the efficacy of antibiotics. However, the need for and the best time for surgery for large Buruli ulcers requires clarification. We recommend confirmation by ZN stain at the rural health centers, since surgical intervention without delay may be necessary on the ZN positive cases to avoid progression of the disease. PCR negative patients were most likely not BU cases. Correct diagnosis and specific management of these non-BU ulcers cases are urgently needed.This study was supported by the Directorate-General for Development and Cooperation (DGDC), Brussels, Belgium, the European Commission (International Science and Technology Cooperation Development Program) (project no. INCO-CT-2005-051476-BURULICO), and by a grant from the Health Services of Fundacao Calouste Gulbenkian. K.K. was supported by a grant from DGDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Introduction: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. Methods: We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. Results: The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. Discussion: This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background Liraglutide 3\ub70 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3\ub70 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2\ub77 times longer with liraglutide than with placebo (95% CI 1\ub79 to 3\ub79, p<0\ub70001), corresponding with a hazard ratio of 0\ub721 (95% CI 0\ub713\u20130\ub734). Liraglutide induced greater weight loss than placebo at week 160 (\u20136\ub71 [SD 7\ub73] vs 121\ub79% [6\ub73]; estimated treatment difference 124\ub73%, 95% CI 124\ub79 to 123\ub77, p<0\ub70001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3\ub70 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding Novo Nordisk, Denmark